21 May 2025
This presentation outlines the key success factors driving high-impact oncology drug development, with a focus on translating innovative science into clinically and commercially meaningful outcomes. It highlights a comprehensive framework encompassing differentiated and validated biology, robust and translatable preclinical data, strategic indication selection, optimized trial design with regulatory alignment, combination potential with standard-of-care therapies, and operational excellence in execution. Each element is illustrated with actionable insights to demonstrate how these principles converge to increase the probability of success in a competitive and fast-evolving oncology landscape.
